

## **ASX: EIQ RELEASE**

13 September 2024

## **S708A CLEANSING NOTICE**

**Sydney:** AI & Medical Technology company Echo IQ (the Company) (ASX:EIQ) has issued 47,366,667 fully paid ordinary shares (Shares) pursuant to settlement of the placement announced to the market on 6 September 2024, utilising its existing placement capacity under Listing Rule (LR) 7.1A. The Company has also issued 3,500,000 consultancy Shares utilising its existing placement capacity under Listing Rule LR 7.1. The Company relies on section 708A of the Corporations Act 2001 (Cth) ("the Act") in relation to the Issue.

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The Shares were issued without disclosure to the investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001. The Company, as at the date of this notice, has complied with:

- the provisions of Chapter 2M of the Corporations Act 2001; and
- Section 674 and 674A of the Corporations Act 2001.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.

- ENDS -

## Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries: Philip Woolff, Chief Operating Officer philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries: Andrew Grover, Executive Chair Andrew.grover@echoiq.ai / investor@echoiq.ai

## ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.



ECHO IQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 2.114 / 477 Pitt Street, Sydney NSW 2000 Australia